Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-803 + durvalumab
- Development stage
- Unknown
- Lead developer
- ImmunityBio
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravesical, Intravenous
01
Overview
N-803 (nogapendekin alfa inbakicept-pmln, brand name Anktiva) is a novel immunotherapy classified as an IL‑15 receptor agonist. It stimulates the immune system by activating natural killer (NK) cells and CD8+ T cells, enhancing anti-tumor activity. Durvalumab (brand name Imfinzi) is a monoclonal antibody that targets programmed death-ligand 1 (PD-L1), blocking its interaction with PD‑1 and CD80 to promote immune-mediated tumor cell destruction. The combination of N‑803 and durvalumab is being investigated for synergistic effects in cancer immunotherapy, particularly after progression on checkpoint inhibitor therapy. Both drugs are biologics developed for oncology indications, including bladder cancer and non-small cell lung cancer[2][6][8].
- Brand names
- AnktivaImfinzi
- Other names
- N803N-803N 803nogapendekin alfa inbakiceptdurvalumab injection
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on N-803 + durvalumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-803 + durvalumab.